Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

BACKGROUND: Nonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet(®)) in combination with trastuzumabHerceptin(®) (Hoffmann-La Roche) has shown promising activity and cardiac safety. We conducted a randomized phase...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V. F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R. H., Matera, J., Azarnia, N., Hudis, C. A., Rozencweig, M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2014
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433508/
https://ncbi.nlm.nih.gov/pubmed/24401928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt543
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller